Jeffrey
Osterman

Jeffrey Osterman is Chair of Life Sciences Licensing & Collaboration Transactions and a partner in the Intellectual Property & Technology Transactions Group.

Jeffrey regularly advises major pharmaceutical companies in connection with licensing and collaboration agreements and manufacturing and supply arrangements. He has significant experience in numerous transactions involving novel therapeutic modalities, including genetic medicine and AI-assisted target and drug discovery.

Jeffrey also regularly leads the technology and intellectual property aspects of major corporate transactions, including commercial arrangements associated with such transactions; and advises on the treatment of intellectual property matters in bankruptcy cases.

Awards and Recognitions

Ranked Band 1 by Chambers in the Technology category, Jeffrey is described by clients as “by far the premier licensing and collaboration attorney in the country” and “a fierce advocate for his clients, equipped with an arsenal of industry-specific knowledge.” Jeffrey is recognized by the Legal 500 as a “Leading Lawyer” in the Media, Technology and Telecoms: Technology Transactions category and is recommended in the Patents: Licensing, Technology Transactions, Media and Entertainment: Transactional and Healthcare: Life Sciences categories.

Jeffrey is also recognized as a “Global Leader” in New York by IAM Global Leaders and is “Highly Recommended” by IAM Patent 1000, where clients have noted he has “a stellar ability to see the forest through the trees, is a clear and concise draftsman and a constructive negotiator,” and he is “the kind of sophisticated IP lawyer you need on a tough deal – he understands his clients’ industry and business, and fights hard while communicating clearly in negotiations to get to a resolution.”

Jeffrey was recognized as a part of World Intellectual Property Review’s Leaders List, and was named an “IP Star” in the IP Transactions and Trademarks category by Managing Intellectual Property and a “Life Sciences Star” by LMG Life Sciences Guide. He has received numerous recognitions from Best Lawyers in America including “Best Lawyer” for Information Technology Law and Technology Law in New York in 2024 and “Lawyer of the Year” for Technology Law in 2024, 2022 and 2020. Jeffrey was shortlisted for “Practitioner of the Year” for IP Transactions by Managing Intellectual Property’s Americas Awards in 2022. Jeffrey was featured as one of the “500 Leading Dealmakers in America” by Lawdragon in 2025, and has been recognized as a Law360 MVP in the Technology category.

Experience
Jeffrey’s recent experience includes:

• Alkermes in its $2.1 billion acquisition of Avadel Pharmaceuticals
• AnaptysBio in its separation into two independent, publicly traded companies
• DRI Healthcare Trust on the IP aspects of its acquisition of a tiered royalty interest in the U.S. net sales of two treatments for chronic thyroid eye disease from Viridian Therapeutics, for an aggregate purchase price of up to $300 million
• Eli Lilly in dozens of transactions, collaboration and license agreements with numerous companies involving novel therapeutic modalities, including:
  • in its up to $2.6 billion licensing and joint research agreement with ABL Bio for its proprietary blood-brain barrier shuttle platform known as Grabody-B, and a related equity investment
  • in a strategic platform-based collaboration with Ailux, a wholly owned subsidiary of XtalPi, to advance bispecific antibody development
  • in its equity investment in and partnership with Remedium Bio, a portfolio company of Lifespan Vision Ventures, to advance gene therapies for Type 2 diabetes and obesity
  • in its agreement with Insilico, a biotechnology company with a proprietary artificial intelligence drug discovery platform, to leverage Insilico’s platform in order to discover and develop products for the treatment of pathogens resistant to current antibiotics
  • in its $870 million agreement to acquire the worldwide rights to apply FluidCrystal technology, from Camurus, to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health
  • in its $13 million minority investment in Creyon Bio
  • as primary outside counsel in handling transactions addressing the global COVID-19 pandemic
  • in collaboration agreements with AbCellera, a discoverer and developer of therapeutic antibodies which had identified antibodies against COVID-19 within 11 days of the first U.S. infection, and which became an early developer of monoclonal antibody therapy for the virus and emerging variants
  • in its global licensing and research collaboration with Dicerna Pharmaceuticals, focused on the discovery, development and commercialization of new cardio-metabolic disease, neurodegeneration and pain medicines utilizing Dicerna’s proprietary GAlXC RNAi technology platform
  • an evaluation and option agreement with Sangamo Therapeutics, granting Lilly the rights to employ STAC-BBB, Sangamo’s novel proprietary capsid, to advance potential treatments for neurological diseases
  • in an option agreement with Capsigen, for a license to capsids
  • a license and collaboration agreement with Magnet Bio
• GSK in its strategic partnership with LTZ Therapeutics to advance the development of novel myeloid cell engagers (MCEs) to address significant unmet need in oncology
• Metsera in its $10 billion sale to Pfizer, following a series of competing bids for the company by Pfizer and Novo Nordisk
• Progeria Research Foundation with respect to licensing agreements for therapies for Progeria
• Regeneron Pharmaceuticals in settling various patent lawsuits against biosimilar manufacturers of Regeneron’s EYLEA® (aflibercept)